Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
102 USD | +0.01% | +7.11% | +2.00% |
May. 13 | Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales | DJ |
May. 10 | Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Sales forecast by analysts have been recently revised upwards.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- With an enterprise value anticipated at 4.15 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.00% | 209B | - | ||
+31.04% | 682B | C+ | ||
+30.35% | 586B | B | ||
-3.35% | 364B | C+ | ||
+18.08% | 327B | B- | ||
+4.18% | 285B | C+ | ||
+15.53% | 240B | B+ | ||
-8.14% | 203B | A+ | ||
+8.18% | 165B | C+ | ||
-1.46% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NOVN Stock
- NVSEF Stock
- Ratings Novartis AG